NCT03012646View on ClinicalTrials.gov

Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2017

Primary Completion Date

April 30, 2019

Study Completion Date

April 30, 2019

Conditions
Pulmonary HypertensionChronic Obstructive Pulmonary Disease
Interventions
DRUG

Inhaled Treprostinil

Inhaled treprostinil (6 mcg/breath) administered four times daily

Sponsors
All Listed Sponsors
lead

United Therapeutics

INDUSTRY